Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology

Known as: QS-WPAI-SHP TEST, WPAI01TN, Work Productivity and Activity Impairment Questionnaire - Specific Health Problem V2.0 Questionnaire Test Name 
Test names of questionnaire questions associated with the the version 2.0 of the work productivity and activity impairment specific health problem… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Micro‐Abstract Data from REVEAL (Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices; n… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2018
Review
2018
BackgroundPatients with the myeloproliferative neoplasms (MPNs) myelofibrosis (MF), polycythemia vera (PV), and essential… 
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Review
2017
Review
2017
Background Ixekizumab (IXE), a monoclonal high affinity antibody that selectively targets interleukin-17A, was superior to… 
2016
2016
To assess patient‐reported outcomes (PROs) in patients with overactive bladder (OAB) receiving the novel β3‐adrenoceptor agonist… 
Highly Cited
2015
Highly Cited
2015
OBJECTIVE The aim of this study was to determine the extent to which structural damage, clinical disease activity, demographic… 
2014
2014
OBJECTIVE The objective of this study was to obtain initial reactions and suggested modifications to two existing presenteeism… 
Review
2013
Review
2013
Objectives: PERFORM (Prospective Epidemiological Research on Functioning Outcomes Related to Major depressive disorder) is a 2… 
Highly Cited
2008
Highly Cited
2008
To examine the effect overactive bladder (OAB) and other lower urinary tract symptoms (LUTS) on health‐related quality of life… 
2008
2008
ABSTRACT Objective: Assess changes in resource utilization, work and activity impairment, and health utility among OAB patients… 
Review
2007
Review
2007
Objective: The effect of adalimumab on patient‐reported outcomes (PROs) was evaluated in patients with moderate to severe…